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Background: Familial Mediterranean fever (FMF) which is an autosomal 
recessive condition that primarily affect population of the Mediterranean basin. 
If undiagnosed effectively and treated with colchicine for life it may lead to 
serious consequences in terms of renal amyloidosis and renal failure.
Objectives: We aim to check for the presence of FMF mutations in clinically 
suspected Egyptian patients, as an important step for family counseling and 
case management.
Subjects and Methods: The study is a pilot study to check for the presence of 
FMF mutations among suspected cases (24 cases) from Sharkia Governorate. 
The control subjects (24) were selected from healthy volunteers. We examined 
FMF mutations by PCR technique for MEFV gene analysis in order to establish 
a diagnosis of FMF by examining two mutations, M694V and E148Q.
Results: We found 58.3% (14/24 cases) of cohort were positive for M694V 
mutation, and all cohort were negative for E148Q mutation. The normal 
controls were negative for previous two mutations.
Conclusions: PCR technique provides a rapid, reliable, cost-effective, 
noninvasive, and sensitive test for establishing a diagnosis of FMF in 
symptomatic patients and also provides a rational basis for medical and genetic 
counseling of FMF patients and their families.
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INTRODUCTION                                                                     
Familial Mediterranean fever (FMF) is 
an autosomal recessive inherited auto-
inflammatory disorder, which is fre-
quent in populations originating from 
the Mediterranean basin.1 It is a febrile 
disease characterized by acute, sponta-
neously resolving episodes of fever and 
pain caused by serosal inflammation 
and associated with mutations in the 
FMF gene, (MEFV).2 The MEFV gene 
was independently cloned by American 
and French groups in 1997: The protein 
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encoded by the MEFV gene has been 
named pyrin by an American group for 
its role in anti-pyrexia. It has been hy-
pothesized that the wild-type pyrin nor-
mally regulates inflammation via apop-
totic speck-like protein. In FMF, how-
ever, the pyrin derived from the mutated 
gene seems to lose the ability to regu-
late the normal inflammatory process, 
particularly that part of the process due 
to the production of IL-1β and nuclear 
factor-kB (NF-kB)3. Pyrin belongs to a 
class of proteins involved in the regula-
tion of apoptosis and inflammation. Its 
N-terminal pyrin domain interacts with 
the ASC adaptor protein, regulating 
caspase-1 activation and consequently, 
IL-1β production. Mutations interfere 
with the role of the pyrin domain, al-
lowing an uninterrupted inflammatory 
cascade.4 
The MEFV gene locates on short arm of 
chromosome 16 and includes 10 exons 
and it encodes 781-amino-acid protein. 
To date, 142 mutations have been iden-
tified in the MEFV gene, most of which 
are substitutions. Of these mutations, 
five account for more than 70% of FMF 
cases – V726A, M694V, M694I, M680I 
and E148Q and have different frequen-
cies in classically affected populations. 
Forty-eight of the MEFV mutations are 
found in exon 105. Mutation E148Q in 
exon 2 was found to be the second most 
common mutation occurring in patients 
of several ethnicities with different hap-
lotypes6. Exons 2 and 10 are the most 
frequent mutation regions of the MEFV 
gene. Half of the FMF population car-
ries two mutations, while 30% and 20% 
carry a single mutation and no identifi-
able mutation, respectively.7
The FMF disorder is characterized by 
recurrent episodes (Exacerbations and 
remissions) of unprovoked inflamma-
tion involving the joints; the pleural and 
peritoneal cavities; and less frequently; 
the skin. FMF peritonitis, the most 
common manifestation of this disease, 
may resemble acute abdomen, leading 
to laparotomy and appendectomy that 
reveal only an inflamed peritoneum and 
neutrophilic exudates. If a surgical pro-
cedure is avoided, the attack resolves 
spontaneously8. In these cases, proper 
genetic consultation may suggest early 
introduction of colchicine. 
Many Egyptian populations have been 
investigated for MEFV gene mutations. 
However, data from FMF patients from 
Sharkia region are still lacking. So the 
purpose of this study is to use PCR 
technique for MEFV gene analysis in 
order to establish a diagnosis of FMF in 
symptomatic patients and to perform a 
preliminary population genetic study in 
Sharkia region.9 
SUBJECTS AND METHODS                                   
The study is a pilot study to check for 
the presence of FMF mutations among 
suspected cases (24 cases) from Shark-
ia Governorate presenting to the Inter-
nal Medicine and Tropical Medicine 
Departments of Zagazig University 
Hospitals and outpatient clinics of Za-
gazig university hospitals during the 
years 2007-2009. The control subjects-
were selected from healthy volunteers. 
The study and the control group were 
matched in regard of age and sex. In-
formed consent had been obtained from 
patients and controls. All patients were 
subjected to full analytic history and 
clinical examination, including: age, 
sex, consanguinity, family history of 
FMF, attacks of abdominal pain, ar-
thralgia or arthritis, chest pain, bone 
aches, renal affection, duration of at-
tacks, effect of colchicine on frequency 
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and duration of attacks, organ involve-
ment. Routine investigations specially 
Urine analysis were also done. 
Clinical Scoring was evaluated accord-
ing to Tel-Hashomer Criteria for diag-
nosis of FMF:10 Major Criteria: 
1. Recurrent febrile episodes accom-
panied by peritonitis, pleuritis, or 
synovitis.
2. Amyloidosis of A type without pre-
disposing disease. 
3. Favorable response to continuous 
colchicine treatment; Minor Crite-
ria: 
A. Recurrent febrile episodes. 
B. Erysipelas - like erythema3 
C. positive history of FMF in first de-
gree relative; Definite Diagnosis= 2 
major, Or 1 major+2 minor, Prob-
able diagnosis 1 major+1 minor. 
In this study we use standard PCR 
technique for MEFV gene analysis in 
order to establish a diagnosis of FMF 
by examining two mutations, M694V 
and E148Q and to determine whether 
the clinical severity of the disease phe-
notype correlates with the nature of the 
mutation among Egyptians.
1- DNA extraction and purification
Venous blood sample (~3 ml) from each 
patients were collected on EDTA (eth-
ylenediamine tetraacetate) containing 
tubes, DNA was extracted promptly us-
ing DNA extraction and purification kit 
(Roche, Germany) according to manu-
facturer’s instructions and then stored 
at -20°C till use.
2- Quantification of genomic DNA
Spectrophotometric optical densities of 
260nm and 280nm were used to investi-
gate the DNA quantity. DNA purity was 
measured using the appropriate ratio of 
OD260: OD280 (1.65-1.85). Concen-
trations (ng/μl) and A260/A280 read-
ings were recorded for each sample.
The extracted DNA concentration was 
measured and adjusted by dilution to 
conc. 20-25 ng/μl prior to PCR us-
ing deionized bi-distilled, sterile water 
(Fluka, Germany).
3- Oligonucleotide primers
All primers used in this study were syn-
thesized by (Tib Molbiol, Berlin, Ger-
many) and obtained in a lyophilized 
state11.
All primers were solved before use to 
obtain a final concentration of 20 pmol/
μl of each. These primers make ampli-
fication for mutations that were cod-
ing regions of the E148Q and M694V 
mutation in the MEFV gene with the 









4- DNA amplification and Mutation 
analysis
PCR was carried out on PCR system 
9700 (Roche, Syngapore). For each se-
ries, a master mix was prepared. 
Each DNA sample was tested for the 
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two mutations (M694V and E148Q). 
All amplicons were stored at 4ºC until 
separation by gel electrophoresis. The 
PCR amplification was performed in a 
final volume of 25µL containing 100 
ng of purified genomic DNA, 0.04 U of 
Ampli Taq Gold (Roche, Germany) and 
its 1x PCR buffer (contains 15 mmol 
of MgCl2 per L), 0.2 mmol of deoxy-
nucleoside 5’-triphosphate mix per L 
(Roche, Germany) and 10 pmol of each 
primer.
The procedure was carried out as fol-
lows: The reaction was heated to 94°C 
for 10 minutes for denaturation, fol-
lowed by 35 cycles with denaturation at 
94°C for 10 seconds, annealing at 60°C 
for 10 seconds and extension at 72°C 
for 30 seconds. Final extension was 
done for 10 minutes at 72°C.
Then the PCR products were separated 
by electrophoresis on a 2% agarose gel 
(Sigma). Ethidium bromide staining of 
the agarose gel was used to detect the 
amplified fragments. 
5- Agarose gel electrophoresis ex-
amination for identification of PCR 
products 
Together with the different amplicons 
were separated on 2% w/v agarose 
gel, tris-base/borate buffer stained 
with 0.01% ethidium bromide solution 
(0.5 mg/L). 10 μl of all amplicons and 
DNA marker were added before gel 
electrophoresis to μl xylenecyanol dye 
solution (1 mg xylenecyanol, 400 mg 
sucrose and completed to 1 ml with wa-
ter) and then subjected to electropho-
resis for 45 min. The amplicons were 
made visible by ethidium bromide. The 
results from gel electrophoresis were 
visualized on a UV transillumination 
(254 nm). Agarose gel preparation as 
well as electrophoresis were carried out 
using buffer solution (pH 8.0), contain-
ing 45 mmol/L Tris-base/boric acid and 
1 mmol/L EDTA adjusted with hydro-
chloric acid.To determine the size of 
the DNA fragments, DNA of a known 
size (100 bp DNA marker, Roche, Ger-
many) was used. 
RESULTS                                                                       
Analysis of the presenting clinical man-
ifestations of studied patients, showed 
that non of them had a positive family 
history for FMF. Parental consanguin-
ity was positive in 16.66% of these pa-
tients. Recurrent febrile episodes and 
abdominal pain were reported in 95.8% 
of patients. Peritonitis affects 87.5% of 
all patients. Joints affection during at-
tacks were: arthralgia (54.16%), arthri-
tis (20.8%) and bone aches (83.3%). 
Chest pain was a symptom in 41.6% of 
patients. Pleuritis in 20.8% of patients. 
20.8% from all patients underwent sur-
gical operations; 4.16% of them under-
went laparotomy and appendectomy 
in 8.3% of them and tonsillectomy in 
8.3% of patients. No Skin erythema 
was reported in all patients. Proteinuria 
suggestive for renal amyloidosis was 
found in 8.3% of patients.
The results of examined FMF M694V 
and E148Q mutations showed that 
58.3% (14 cases) had positive muta-
tions for M694V mutation, while all our 
patients were negative for E148Q muta-
tion. The normal controls were negative 
for previous two mutations.
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Fig. 1: Detection of the of the MEFV gene in different blood samples. DNA was extracted from different 
samples and examined by PCR-analysis using primer pair M694V for PCR-analysis. Lane 1: DNA lad-
der100 bp, lanes from 2- 8 were PCR products of normal controls, Lanes from 9 – 15 were PCR products 
from patients samples, lanes 9,10,12 and 14 showed positive bands at 300 bp for M694V mutation. Other 
patients samples were negative.
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Fig. 2: Detection of the of the MEFV gene in different blood samples. DNA was extracted from different 
samples and examined by PCR-analysis using primer pair E148Q for PCR-analysis. Lane 1: DNA lad-
der100 bp, lanes from 2- 8 were PCR products of normal controls, Lanes from 9 – 15 were PCR products 
from patients samples. All samples were negative for E148Q mutations.
64
Common MEFV mutations in Egyptian patients with FMF
DISCUSSION                                                                      
Familial Mediterranean fever (FMF) is 
an autosomal recessively-transmitted 
disease characterized by attacks of fe-
ver and serositis12 MEFV gene muta-
tions are responsible for the disease.13 
This gene was discovered firstly in 1997 
(Mediterranean Fever – MEFV) and 
this has created possibilities to study 
the distribution of various mutations in 
geographically and ethnically different 
populations.5
Traditionally, the diagnosis of FMF has 
been based on clinical manifestations 
and the physician’s experience. Fol-
lowing the cloning of MEFV, genetic 
analysis of its mutations has become a 
useful adjunct for establishing or con-
firming the diagnosis of FMF.14 
In this study, recurrent febrile episodes 
and abdominal pain were the most com-
mon features (95.8%) followed by peri-
tonitis (87.5%), joint affection by bone 
aches (83.3%), arthralgia (54.16%) 
or arthritis (20.8%) and chest pain 
(41.6%) or pleuritis (20.8%). Interest-
ingly, 20.8% of cases had undergone 
surgery either appendectomy (8.3%), 
tonsillectomy (8.3%) or laparotomy 
(4.16%). Proteinuria suggestive for 
amyloidosis was found in (8.3%) of pa-
tients. No skin erythema. In comparison 
with our study, Zekri, et al.15, reported 
in his Egyptian patients that the clinical 
features were: fever (100%), abdominal 
pain (95%), arthritis (55%), pleurisy 
(40%) with no skin rash or pericarditis. 
Also they have reported that 25% of the 
cases had a past history of appendecto-
my or laparotomy15. Another Egyptian 
study was done by Settin, et al8. who 
found that abdominal pain was the most 
common symptom (87.9%) followed 
by fever (82%), arthritis or arthralgia 
(56.1%), chest pain (45%) and myalgia 
(6%). Laparotomy had been done dur-
ing attacks for exploration or appendec-
tomy in 27% of cases. 
In a group of Arab patients, the most 
common manifestations were peritoni-
tis (93.7%), arthritis (33.7%) and pleu-
risy (32%). The authors reported lack 
of manifestations of amyloidosis, skin 
lesions, organomegaly and lymphade-
nopathy16. On the other hand, in another 
study on arab children, Rawashdeh and 
Majeed17 reported that 82% had recur-
rent abdominal pain, 43% had pleurisy, 
37% had arthritis, 15% had cutaneous 
manifestations, 12% had splenomegaly 
and 4% had hepatomegaly17. Tunca, et 
al.18 studied a large series of Turkish 
cases and noted that their clinical fea-
tures included peritonitis (93.7%), fe-
ver (92.5%), arthritis (47.4%), pleuritis 
(31.2%), myalgia (39.6%) and erysipe-
las-like erythema (20.9%). 
We found positive M694V mutation 
in 58.3% of all studied patients, which 
consistent with Settin, et al.8 who 
found that in their 66 patient, M694V 
was the most common allelic mutation 
found followed by V726A then M680I 
(18.8%, 17.42% 12.1% respectively).
The difference in percentage between 
our result and their may refer to differ-
ent number of cases. In another study 
in Egypt, Zekri, et al.15 reported that 
the M694V mutation was detected in 
100% and V726A mutation in 85% of 
their cases. El Shanti, et al.19 found that 
M694V mutation was the most com-
mon MEFV mutation between Arabs, 
although it is less common than in 
other ethnic groups. Al Alami, et al.20 
studied Arabic population from Egypt, 
Syria, Iraq and Saudi Arabia and found 
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that 53.4% are mutation positive with 
mutational types M694V and V726A 
are the most common. Another study 
from Jordan found that 59% had 1 or 
2 mutations, of the studied mutations 
M694V, V726A, M680I, accounted 
for 38%, 26%, 10%, respectively21. In 
Syria, 89% were positive either for one, 
two or three mutations. The allelic fre-
quency of M694V, V726A, M680I mu-
tations was in the form of 45.8%, 26%, 
4.8% respectively22. On the other hand, 
Öztürk, et al. reported that M694V was 
detected in only 4.5% of the studied 
chromosomes of Egyptian patients.23 
Among north Africa population, the 
most frequent mutations were M694V 
and M694I. These mutations account 
for different proportions of the MEFV 
mutations in Algeria (5%, 80%), Mo-
rocco (49%, 37%) and Tunisia (50%, 
25%). They pointed out that M694I mu-
tation is specific to the Arab population 
from Maghreb.24
We found that all studied patients are 
negative for E148Q Mutation which 
agree with study by Al-Alami and his 
colleagues20 who indicated that E148Q 
had reduced penetrance in the Arab 
population and thus a proportion of 
the genetically affected individuals re-
main asymptomatic. El Shanti, et al.19 
reported that E148Q mutation was the 
least penetrant and might be a polymor-
phism. It has been identified in Arab 
patients alone and in a complex allele 
with other exon 10 mutations, but is 
generally seen in healthy carriers. This 
may be noteworthy due to the use of the 
restriction endonuclease digestion test 
for the detection of the E148Q muta-
tion that can lead to misdiagnosis in the 
presence of the E148V mutation, which 
could artificially increase the number 
of individuals identified as carriers of 
the E148Q mutation. Al Alami, et al.20 
found that the E148Q mutation was 
the most common among the healthy 
adult cohort, but was not present in af-
fected individuals. On the other hand 
in cases from Tunis 18% were positive 
for E148Q mutation25. Among Leba-
nese patients, Sabbagh, et al.26, reported 
that the most important feature in their 
study was the relatively high frequency 
of E148q that allowed them to ques-
tion it as mutation rather than polymor-
phism. It was the second most common 
mutation in their study group (22.2%), 
while M694V mutation was found to be 
the most common (26.1%).
In 2007, Lidar and Livneh4, reported 
that around 80% of FMF patients have 
an identifiable MEFV mutation, 57% 
have two mutations, 26% have a single 
mutation, while 16% have no identifi-
able mutation and the majority of cases 
are caused by four mutations clustered 
on a single exon: M694V, V726A, 
M680I and M694I. The prevalence of 
which varies according to the popula-
tion studied. They also added that the 
role of the exon 2, E148Q mutation, 
as a disease-causing mutation is con-
troversial. This non-founder mutation 
is found in populations in which FMF 
is distinctly rare, such as the Japanese, 
Chinese and Punjabi Indians. Addition-
ally, E148Q homozygotes are rarely 
found in the FMF population.4
FMF is a recessively inherited disease, 
finding two mutations does not neces-
sarily confirm the disease genetically. 
Phasing by analysis of the parent’s 
DNAs is mandatory, especially if one of 
the two mutations is E148Q, a low-pen-
etrance mutation frequent (up to 4%) in 
the general population.27
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Yepiskoposyan and Harutyunyan,5 re-
ported FMF inflammatory attacks can 
be triggered by stress and extreme 
physical exercise. In general, the effect 
of environment on the inflammatory at-
tacks in FMF is not surprising and is also 
seen in other cyclic conditions such as 
sickle cell anemia. However, in contrast 
to the latter, where only one mutation 
exists, in FMF, predisposition to the 
influence of environment is dependent 
on which mutations are present. This is 
confirmed by stronger predisposition in 
the M694V homozygotes. 
In conclusion FMF is mainly a clini-
cally diagnosed disease with validated 
diagnostic criteria and it necessitating 
a high index of suspicion in patients 
from high-risk ethnic groups. PCR 
technique provides a rapid, reliable, 
cost-effective, non invasive and sensi-
tive molecular genetic test for establish-
ing a diagnosis of FMF in symptomatic 
patients and provides a rational basis 
for medical and genetic counseling and 
clinical treatment of FMF patients and 
their families, but we recommended 
studying other mutations of MEFV 
gene in Sharkia region on large scale of 
population.
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